Tumor hypoxia detected by 18F-fluoromisonidazole positron emission tomography (FMISO PET) as a prognostic indicator of radiotherapy (RT)

I Tachibana, Y Nishimura, K Hanaoka… - Anticancer …, 2018 - ar.iiarjournals.org
Background/Aim: 18F-misonidazole positron emission tomography (FMISO PET)/computed
tomography (CT) obtained before and during radiotherapy (RT) was analyzed as to whether …

Quantifying regional hypoxia in human tumors with positron emission tomography of [18F] fluoromisonidazole: a pretherapy study of 37 patients

JS Rasey, W Koh, ML Evans, LM Peterson… - International Journal of …, 1996 - Elsevier
Purpose: To assess pretreatment hypoxia in a variety of tumors using positron emission
tomography (PET) after injection of the hypoxia-binding radiopharmaceutical [“'F] …

A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before …

I Tachibana, Y Nishimura, T Shibata… - Journal of Radiation …, 2013 - academic.oup.com
To visualize intratumoral hypoxic areas and their reoxygenation before and during
fractionated radiation therapy (RT), 18F-fluoromisonidazole positron emission tomography …

FMISO as a biomarker for clinical radiation oncology

S Zschaeck, J Steinbach, EGC Troost - Molecular Radio-Oncology, 2016 - Springer
Tumour hypoxia is a well-known negative prognostic marker in almost all solid tumours.[18F]
Fluoromisonidazole (FMISO)-positron emission tomography (PET) is a non-invasive method …

Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy

SM Eschmann, F Paulsen, M Reimold… - Journal of nuclear …, 2005 - Soc Nuclear Med
In radiotherapy of head and neck cancer (HNC) and non-small cell lung cancer (NSCLC),
hypoxia is known to be an important prognostic factor for long-term survival and local tumor …

Review of positron emission tomography tracers for imaging of tumor hypoxia

SK Imam - Cancer biotherapy & radiopharmaceuticals, 2010 - liebertpub.com
Hypoxia plays a critical role in tumor development and aggressiveness and is an important
prognostic factor for resistance to antineoplastic treatments; therefore, it is required to …

Hypoxia-imaging with 18F-misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer

SM Eschmann, F Paulsen, C Bedeshem… - Radiotherapy and …, 2007 - Elsevier
BACKGROUND AND PURPOSE: PET with 18F-Misonidazole (FMISO-PET) is a non-
invasive method for measuring tumor hypoxia. We analysed changes of FMISO-uptake …

High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer

S Okamoto, T Shiga, K Yasuda, YM Ito… - Journal of Nuclear …, 2013 - Soc Nuclear Med
Tumor hypoxia is well known to be radiation resistant. 18F-fluoromisonidazole (18F-FMISO)
PET has been used for noninvasive evaluation of hypoxia. Quantitative evaluation of 18F …

Influence of the scan time point when assessing hypoxia in 18F-fluoromisonidazole PET: 2 vs. 4 h

K Kobayashi, O Manabe, K Hirata, S Yamaguchi… - European Journal of …, 2020 - Springer
Abstract Purpose 18 F-fluoromisonidazole (18 F-FMISO) is the most widely used positron
emission tomography (PET) tracer for imaging tumor hypoxia. Previous reports suggested …

Tumor hypoxia: a new PET imaging biomarker in clinical oncology

N Tamaki, K Hirata - International journal of clinical oncology, 2016 - Springer
Tumor hypoxia is associated with tumor progression and resistance to various treatments.
Noninvasive imaging using positron emission tomography (PET) and F-18-labeled …